Stocks · News reference
Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials sits well clear of the lower group, separated by a margin several times wider than any other gap in the table.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease (CD).
Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.
RBC Capital analyst Trung Huynh reiterates AbbVie (NYSE:ABBV) with a Outperform and maintains $280 price target.
Barclays analyst Aleksey Yefremov initiates coverage on Air Products (NYSE:APD) with a Overweight rating and announces Price Target of $353.
Nine of 11 sectors are higher in Monday’s regular session, with cyclical sectors holding two of the top three positions. The leaders are separated rather than clustered, with Energy, Communication Services and Financials setting a varied pace across the top of the table.
ASML posts strong Q3 2026 sales as CEO Christophe Fouquet signals possible capacity expansion beyond 2028 amid surging AI demand.